rosacea
ROSACEA
Rosacea is a chronic cutaneous disease of the convexities of the central face (cheeks, chin, nose and central forehead) w/ periorbital and perioral skin sparing. This condition is attributed to chronic vasodilation.
Remissions and exacerbations are common.
It typically appears after 30 years of age but may occur at any age.  It commonly affects fair-skinned individuals.
The common presenting symptoms are facial flushing, stinging/burning erythema, telangiectasia, edema, papules, pustules, ocular lesions, and hypertrophy of the sebaceous glands of the nose with fibrosis.
A history of episodic flushing often heralds onset of rosacea.
Drug Information

Indication: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; otitis me...

Indication: Acne vulgaris.

Indication: Infections caused by susceptible bacteria, as an alternative drug in the treatment of infections in women caus...

Indication: Nasopharyngeal, lower resp tract, skin & soft tissue infections.

Indication: Infections caused by clarithromycin-sensitive pathogens: Nasopharynx (eg, tonsillitis, pharyngitis), paranasal...

Indication: Upper resp tract infections eg, strep pharyngitis/tonsillitis, acute maxillary sinusitis; lower resp tract inf...

Indication: Serious infections caused by clindamycin-susceptible strains of streptococci, pneumococci & staphylococci ...

Indication: Acne vulgaris, especially during inflammed papulopustulary phase.

Indication: Acne vulgaris.

Indication: Cutaneous treatment of acne vulgaris where comedones, papules & pustules predominate. Face acne, chest or ...

2  /  10
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2019
Being infected with Helicobacter pylori appears to increase the risk of developing diabetes among Chinese adults, a new study reports.
Audrey Abella, 06 Aug 2019
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.